prev

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%efficacy for prevention of cervical cancer and precancerous lesionsassociated with the human papillomavirus (HPV) types targeted bythe vaccine, conclude authors of an Article published early Onlineand in the upcoming issue of The Lancet. HPV types 16 and 18 account for 70% or morecases of cervical cancer worldwi...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated(Nasdaq:INSM), a biopharmaceutical company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet medical needs, today noted the publication ofpromising results of research from three universities regarding thepotential role of insulin-like growth factor binding protein-3(IGFBP-3) in...

Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates

'Superbug' Prevalence Data from 1,237 Facilities DemonstratesPublic Health Threat; Colonization and Infections Span All States,Across Healthcare Facility Units SAN JOSE, Calif., June 25, 2007 /PRNewswire-USNewswire/ -- TheAssociation for Professionals in Infection Control and Epidemiology(APIC) today released initial results from a nationwide study of1,237 U.S. healthcare facilities, exam...

Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

Broadest, Most Comprehensive Survey Provides New Benchmark on MRSAin Healthcare Facilities WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- Thefollowing was released today by APIC: WHAT: -- First nationwide study of the prevalence of Methicillin-resistant Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism, in U.S. healthcare facilit...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network)-- Endo Pharmaceuticals Inc., a wholly owned subsidiary of EndoPharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented resultsfrom a Phase III randomized, double-blind, placebo-controlledclinical trial evaluating Frova (frovatriptan succinate) 2.5 mgtablets as a six-day preventative treatment in women withdifficult-to-tre...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill

First significant drug safety measure in 45 years; focus moves toHouse WASHINGTON, May 09, 2007 /PRNewswire-USNewswire/ -- The Senatetoday overwhelmingly passed significant prescription drug safetyreforms to give the Food and Drug Administration more power to dealwith unsafe medicines on the market, moving the issue of drugsafety to the House, where a strong bill has been introduced buth...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--May 17, 2007 - Resultspublished this week in The Lancet show that Merck's cervical cancervaccine, GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11,16, 18) Recombinant Vaccine) was 100 percent effective inpreventing high-grade vulvar and vaginal dysplasias caused by HPVtypes 16 and 18, two types strongly associated with these diseases.The 10...

Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of18 investigator-initiated trials related to the Company's productswill be presented at Digestive Disease Week(R) 2007, which will beheld May 19-24, 2007. Digestive Disease Week is considered thelargest and most prestigious meeting in the world for the GIprofessional. Every...

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants VersusCurrent Standard of Care and Shows Reduction of Medically AttendedOutpatient RSV- Related Lower Respiratory Infections - TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.today announced positive results from a large prospective trialconducted for prevention of respiratory syncytial virus (RSV). Thetrial compared...

Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ --Viragen, Inc. and Viragen International, Inc. today announcedresults from a sponsored in vitro study conducted at UmeaUniversity in Sweden, which found that Multiferon(R) (multi-subtype, human alpha interferon) suppressed development ofresistant human melanoma clones to a far greater degree thanrecombinant alpha interferon. The stud...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in aPrevious Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. today announced that investigatorsat St. Jude Children's Research Hospital, Memphis, TN, reportedfavorable results evaluating peramivir treatment in an animal modelof influenza using a highly virulent strain of H5N1 virus (an avia...

Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years

ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new Harris Pollsuggests that the flu vaccine used before last winter may have beenless effective than the vaccines used in some previous years. Theadults who had flu shots before last winter were only 24 percentless likely to get the flu than those who were not vaccinated. Thedifferences were larger in two previous Harris Polls on the samet...

Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - AvanirPharmaceuticals (NASDAQ:AVNR) today announced that data on thelong-term safety of the investigational drug Zenvia(TM)(dextromethorphan / quinidine) and the prevalence of InvoluntaryEmotional Expression Disorder (IEED) were presented today during aposter session at the American Academy of Neurology (AAN) 59thAnnual Meeting in Boston....

deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced positive top-line results from itsPhase I multiple dose clinical trial of DG051, which the company isdeveloping for the prevention of heart attack. In the study, arandomized, double-blind, multi- dose, ascending dose,placebo-controlled clinical trial, a total of 40 healthy subjectswere exposed to DG...

Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest

BOSTON--(BUSINESS WIRE)--Apr 26, 2007 - A new study published todayin the New England Journal of Medicine ("A National Survey ofPhysician-Industry Relationships") on the extent of doctor andpharmaceutical company relationships, highlights the need forprofession-wide and public policy reforms promoted by ThePrescription Project. The article concludes that the existing,voluntary PhRMA (Pharma...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breakerpresentation at the 42nd Annual Meeting of the European Associationfor the Study of the Liver (EASL), researchers today presented datafrom a planned interim analysis of the PROVE 1 clinical trial,which is the first trial to evaluate short-duration therapy withthe investigational hepatitis C protease inhibitor telaprevir (TVR,...

Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)

BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New datasupporting the clinical development of telaprevir (VX-950), one ofthe most advanced investigational oral protease inhibitors for thetreatment of hepatitis C virus (HCV) infection, will be presentedat the 42nd Annual Meeting of the European Association for theStudy of the Liver (EASL) in Barcelona this week. In total, nineabstracts re...

First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America

In Response, Health Organizations Unite to Help Educate on GoodDiabetes Management and How to Reduce the Risk of Other SeriousHealth Problems SEATTLE, April 10, 2007 /PRNewswire/ -- A first-of-its-kindreport looking at the prevalence and cost of type 2 diabetescomplications shows that an estimated three out of five people(57.9 percent) with type 2 diabetes have at least one of the others...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - InotekPharmaceuticals Corporation announced today the publication in thejournal Stroke of preclinical animal data showing that theadministration of a poly(ADP-Ribose) polymerase (PARP) inhibitorhas a large protective effect on the survival of certain braincells following a stroke. PARP is a nuclear enzyme that directs therepair of damaged DNA...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

BETHESDA, Md., April 1, 2007--Rapamycin, an FDA-approved drugnormally used to help prevent the body from rejecting organ andbone marrow transplants and also used to coat cardiac stents, washighly effective in preventing the development of tobacco-relatedlung tumors in mice. In a study published in the April 1, 2007issue of Clinical Cancer Research, researchers at the NationalCancer Insti...

Six Important Things to Know About Preventing Hospital Infections

Infection Control Professional Offers Patient Tips to Guard AgainstHospital Infections KANSAS CITY, Kan., April 02, 2007 /PRNewswire/ -- Hospitalinfections are among the top ten leading causes of death in theUnited States, according to the Centers for Disease Control. Thereare countless stories about patients who go into hospitals withminor conditions and leave under much graver circumsta...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...

GenoMed Prevents Sickle Cell Pain for Over a Year

ST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC PinkSheets:GMED), the Next Generation Disease Management company whosebusiness is public health(TM), announced today publication of acase report of a sickle cell patient whose pain has disappeared forover a year thanks to GenoMed's treatment. The patient is a middle-aged African American woman who foryears required multiple pain pill...